Speakers
Alejandro Amador
Head of High Throughput Biology, Functional Genomics
GlaxoSmithKline
Amr Abdeen
Postdoctoral Associate
University of Wisconsin- Madison
Discussion Day
2:00 pm | Improved Non-Viral Vectors for In Vivo Genome Editing
Ana Moreno
Founder & Chief Executive Officer
Navega Therapeutics
Day Two
Thursday May 21 2020
4:30 pm | Chair’s Closing Remarks
9:30 am | Epigenome Editing using CRISPR to Treat Pain
8:20 am | Chair’s Opening Remarks
Andrew Anzalone
Postdoctoral Fellow
Liu Group, Broad Institute
Day One
Wednesday May 20 2020
8:30 am | Exploring the Potential of Prime Editing
Ben Kleinstiver
Principal Investigator
Massachusetts General
Day Two
Thursday May 21 2020
11:30 am | Broadly Useful Engineered CRISPR-Cas Enzymes with Enhanced Properties
Blair Madison
Senior Director, Genetic Engineering
Poseida Therapeutics
Day Two
Thursday May 21 2020
2:00 pm | Creating Novel Proteins to Optimize Efficacy and Specificity
12:00 pm | Panel Discussion: Do CRISPR Tools Need to be Perfect?
Brett Staahl
Founder & Head of Applied Technologies
Scribe Therapeutics
Discussion Day
9:15 am | Why Isn’t the Future of Medicine Here Yet?
Carlo Zambonelli
Associate Director
Beam Therapeutics
Day One
Wednesday May 20 2020
4:15 pm | Developing Assays and Tools for Base Editing
Carsten Charlesworth
Graduate
Stanford University
Day Two
Thursday May 21 2020
4:00 pm | Utilizing CRISPR to Grow Human Organs for Transplantation
David Schaffer
Co-Founder
4D Molecular Therapeutics
Discussion Day
9:45 am | Directed Evolution of Novel AAV Variants for Clinical Gene Therapy
Delai Chen
Associate Director, Nanoparticle Formulation
Beam Therapeutics
Discussion Day
12:15 pm |
Fyodor Urnov
Scientific Director
Innovative Genomics Institute
Day One
Wednesday May 20 2020
4:45 pm | Chair’s Closing Remarks
8:00 am | KEYNOTE: CRISPR 2030: the Promise and the Challenge
7:50 am | Chair’s Opening Remarks
Jonathan Gootenberg
McGovern Fellow
Harvard University
Day Two
Thursday May 21 2020
10:30 am | CRISPR Diagnostics: Expanding the Nucleic Acid Detection Toolbox by Harnessing Microbial Diversity
Julian Grunewald
Research Fellow
Joung Lab, Massachusetts General
Day One
Wednesday May 20 2020
9:00 am | Developing and Improving Base Editors
Kalina Paunovska
Postdoctoral Fellow
Dahlman Lab, Georgia Tech
Discussion Day
2:30 pm | Delivering CRISPR Apparatus In Vivo Using Nanoparticle Technology
Karl Petri
Research Fellow
Joung Lab, Massachusetts General
Day One
Wednesday May 20 2020
3:45 pm | ONE-seq: Detection of CRISPR Nuclease and Base Editor Off-Targets with Ultra-High Sensitivity to Ensure the Safety of CRISPR Therapeutics
Kate Zhang
Vice President, Biological Development
Editas Medicine
Day One
Wednesday May 20 2020
11:50 am | Optimizing CRISPR/Cas to Translate Efficiently into the Clinic
Killian Hanlon
Research Fellow
Harvard University
Discussion Day
10:15 am | Overcoming Limitations of Viral Vectors to Deliver CRISPR Machinery
Kiran Musunuru
Principal Investigator
University of Pennsylvania
Day Two
Thursday May 21 2020
2:30 pm | Applying CRISPR to Predict and Treat Cardiovascular Disease
Kunwoo Lee
Chief Executive Officer & Co-Founder
GenEdit
Discussion Day
12:15 pm |
11:45 am | Non-Viral Delivery of CRISPR Using Polymer Nanoparticles
Lihua Julie Zhu
Professor & Head of Bioinformatics Core
University of Massachusetts
Luis Barrera
Head of Computational Sciences
Beam Therapeutics
Day Two
Thursday May 21 2020
1:30 pm | Comprehensive Identification of Base Editor Off-Targets in the Context of Therapeutically Relevant Delivery
12:00 pm | Panel Discussion: Do CRISPR Tools Need to be Perfect?
Lumeng Ye
Senior Scientist
GenScript Biotech Corp.
Day One
Wednesday May 20 2020
12:20 pm | Precise, Non-Viral, CAR-T Engineering with CRISPR sgRNA and ssDNA
Marija Tadin- Strapps
Vice President, Exploratory Biology
SQZ Biotechnologies
Discussion Day
3:00 pm | CellSQZ platform for Development of Next Generation Cell Therapies
Niren Murthy
Professor
University of California at Berkeley
Discussion Day
11:15 am | Gene Editing After Local Injection: Non-Viral Delivery
Omar Abudayyeh
McGovern Fellow
Harvard University
Day Two
Thursday May 21 2020
9:00 am | Harnessing Novel CRISPR Tools for Genome Engineering and RNA Editing
Paul Diehl
Chief Operating Officer
Cellecta
Day One
Wednesday May 20 2020
11:30 am | Functional CRISPR Screening and Cell Barcoding to Identify Genes Driving Biological Responses and Disease Progression
Peter Marks
Director, CBER
FDA
Day Two
Thursday May 21 2020
8:30 am | FDA’s Regulatory Approach to Applications of CRISPR
Rafi Emmanuel
Research Director
Emendo Biotherapeutics
Day One
Wednesday May 20 2020
2:45 pm | Target Optimized Variant of CRISPR Associated Nuclease Enables Allele-Specific Knock Out of ELANE-Related Neutropenia
Renee Wegrzyn
Program Manager
DARPA
Day Two
Thursday May 21 2020
11:00 am | Programmable Gene Modulation
Rui Wang
Principal Research Scientist
Abbvie
Sanne Klompe
Graduate
Sternerg Lab, Columbia University
Day One
Wednesday May 20 2020
11:00 am | Utilizing CRISPR-Associated Transposons for Programmed Insertions Without Generating Double-Strand Breaks
Satinder Rawat
Senior Licensing Officer
University of Massachusetts
Day One
Wednesday May 20 2020
2:15 pm | Bridging the Gap Between Academia and Industry: Translating Cutting-Edge Technologies from the Lab to the Clinic
Sicco Popma
Founder, Chief Executive Officer & President
IO Biosciences
Day Two
Thursday May 21 2020
3:30 pm | Developing CRISPR-Based Cell Therapies Using a Proprietary Gene Editing System (GEMS)
Speaker to be Confirmed
Aldevron
Day One
Wednesday May 20 2020
2:00 pm | Slot Reserved for Aldevron
Speaker to be Confirmed
Horizon Discovery
Day One
Wednesday May 20 2020